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1  | INTRODUC TION
Sepsis is characterized by excessive production of inflammatory me-
diators resulting in deregulated host response and organ dysfunc-
tion that includes brain dysfunction. In this context, many studies 
have already reported microglia activation in animal models and hu-
mans.1-7 The primary role of microglia is the maintenance of neural 
cells and synapses during normal functioning of the CNS. Upon 
harmful stimulus, microglia are activated and can have a protective 
role. Activated microglia are very plastic and may exist in multi-
ple phenotypes that present different responses in accordance to 
changes in the cerebral microenvironment. They can induce brain 
repair, or cytotoxicity, as well as immune-regulatory or pro-inflam-
matory functions.8,9
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Abstract
We aim to characterize the kinetics of early and late microglial phenotypes after 
systemic inflammation in an animal model of severe sepsis and the effects of mino-
cycline on these phenotypes. Rats were subjected to CLP, and some animals were 
treated with minocycline (10 ug/kg) by i.c.v. administration. Animals were killed 
24	 hours,	 5,	 10	 and	 30	 days	 after	 sepsis	 induction,	 and	 serum	 and	 hippocampus	
were collected for subsequent analyses. Real-time PCR was performed for M1 and 
M2 markers. TNF-α, IL-1β, IL-6, IL-10, CCL-22 and nitrite/nitrate levels were meas-
ured. Immunofluorescence for IBA-1, CD11b and arginase was also performed. We 
demonstrated that early after sepsis, there was a preponderant up-regulation of M1 
markers, and this was not switched to M2 phenotype markers later on. We found 
that up-regulation of both M1 and M2 markers co-existed up to 30 days after sepsis 
induction. In addition, minocycline induced a down-regulation, predominantly, of M1 
markers. Our results suggest early activation of M1 microglia that is followed by an 
overlap of both M1 and M2 phenotypes and that the beneficial effects of minocy-
cline on sepsis-associated brain dysfunction may be related to its effects predomi-
nantly on the M1 phenotype.
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Classically, microglial and macrophage polarization into M1 and 
M2 phenotypes is often discussed using similar terminology al-
though this dichotomous division is oversimplified.10 Theoretically, 
these different phenotypes can have negative or positive effects on 
adult brain adaptation after damage. When activated as M1 pheno-
type, microglia affect neurogenesis,11,12 secrete pro-inflammatory 
mediators (CD11b, iNOS, CD32, nitric oxide) and worsen long-term 
neurological deficits after damage.13 On the other hand, when ac-
tivated as M2 phenotype, they promote repair, regeneration and 
neuroprotection through markers Arg-1, CCL-22, IL-10, CD206 and 
TGF.12,14 Minocycline has been reported to suppress the production 
of inflammatory mediators (IL-6, TNF-α and IL-1β) induced by LPS 
in peripheral cells15 and has the same effect when injected into the 
brain,3 suggesting an effect mainly on M1 microglia.
The kinetics of microglial polarization during sepsis development 
is not known, and it can have implications in the recovery of brain 
function. Furthermore, the effect of minocycline on microglial phe-
notypes in sepsis is also unknown. Thus, we aimed to characterize 
the kinetics of microglial phenotypes early and late after systemic 
inflammation in an animal model of severe sepsis, and the effects of 
minocycline on these phenotypes.
2  | MATERIAL S AND METHODS
2.1 | Ethics
The experimental procedures involving animals were performed in ac-
cordance with the National Institutes of Health (Bethesda—Maryland, 
USA) Guide for Care and Use of Laboratory Animals and with the 
approval of our institutional ethics committee (protocol number: 
084‐2015/1).	Animals	were	allocated	and	randomized	as	five	animals	
per cage. Only one person knew the groups; all others were blinded in 
surgery for CLP (caecal ligation and perforation) and analyses.
2.2 | Sepsis induction—CLP model
Male Wistar rats were subjected to CLP as previously described.16 
Briefly, animals were anaesthetized using a mixture of ketamine 
(80 mg/kg) and xylazine (10 mg/kg), administered intraperitoneally. 
Under aseptic conditions, a 3 cm midline laparotomy was performed 
to expose the caecum and adjoining intestine. The caecum was li-
gated with a 3.0 silk suture at its base, below the ileocaecal valve, 
and was perforated once with a 14-gauge needle. The caecum was 
then squeezed gently to extrude a small amount of faeces through 
the perforation site. The caecum was then returned to the peritoneal 
cavity, and the laparotomy was closed with 4.0 silk sutures. Animals 
were	 immediately	 resuscitated	with	 saline	 (50	mL/kg)	 subcutane-
ously (s.c.) immediately and 12 h after CLP. All animals received an-
tibiotics	(ceftriaxone	at	30	mg/kg	and	clindamycin	25	mg/kg)	every	
6 hours s.c. for a maximum of 3 days. To minimize variability be-
tween different experiments, the CLP procedure was always per-
formed by the same investigator. The mortality rate of this model is 
around 40%, which is consistent with severe sepsis. We extensively 
characterized acute and long-term cognitive impairment and brain 
inflammation using this animal model.3,17-19
2.3 | Experimental design
Animals were subjected to CLP, and one group was treated with 
a single intracerebroventricular (i.c.v.) injection of minocycline 
(100 µg/kg) immediately after sepsis induction.3 Using this treat-
ment regime, we had demonstrated that minocycline was able to de-
crease brain inflammation, damage and long-term cognitive deficits 
in sepsis survivors.3 Animals were killed immediately after CLP (time 
0),	24	hours,	3,	5,	10	and	30	days	after	sepsis,	and	the	hippocampus	
and	serum	were	removed	and	stored	at	−80°C.	For	all	analyses,	CLP	
time 0 was considered as the reference group.
2.4 | Perfusion tissue fixation for 
immunofluorescence
Animals (five per group) were anaesthetized with cetamina and xy-
lazine (30 and 10 mg/kg i.p). Once the animal was unresponsive to 
toe-pinch response (anaesthesia validation test), it was placed on the 
operating table with its back down. A scalpel was used to make an inci-
sion through its abdomen at the length of the diaphragm, followed by a 
cut of the rib cage up to the collarbone on both sides of the ribs provid-
ing a clear view of the heart. A small incision was made in the poste-
rior end of the left ventricle, and an olive-tipped perfusion needle was 
inserted	through	the	ventricle	to	extend	straight	up	about	5	mm.	An	
incision to the rat's right atrium was made to create an outlet for free 
flow of the solution. A haemostat was used to stabilize the needle and 
to clamp the descendent aorta to optimize perfusion in the CNS. Five 
animals per group were perfused with 0.9% sterile saline for 10 min-
utes (flow rate 20 mL/min) followed by 10 minutes with 4% paraformal-
dehyde (PFA) solution in PBS (pH 7.4) (flow rate 20 mL/min). The brains 
were then carefully extracted and maintained in 4% PFA for 24 hours 
at	4°C,	placed	in	15%	sucrose	for	24	hours	at	4°C	and	then	placed	in	
30%	sucrose	for	24	hours	at	4°C.	Brains	were	slightly	dried	and	frozen	
at	−20°C.	After	24	hours,	the	prefrontal	cortex	and	the	hippocampus	
were	sectioned	in	slices	of	15	μm on the coronal plane using a cryostat 
at	−20°C	(Jung	Histoslide	2000R;	Leica).	A	total	of	20‐30	slices	per	rat,	
containing the structures, were collected in PBS containing 0.1% Triton 
X‐100	(PBS‐0.1%).	The	free‐floating	sections	were	incubated	with	5%	
albumin for 2 hours to block nonspecific binding sites.
The	antibodies	were	incubated	for	48	hours	at	4°C.	Anti‐Iba‐1,	
anti‐CD11b	and	anti‐arginase	were	used	at	1:500	dilution.	DAPI	
was	used	for	nucleic	acid	staining	(1:500;	D9542,	Sigma‐Aldrich).	
Antibodies were diluted in PBS containing 2% bovine serum albu-
min. After washing four times with 0.1% PBS, tissue sections were 
incubated with secondary antibodies according to the reactive 
species	(anti‐rabbit	or	mouse	Alexa	488	or	555	from	Cell	Signaling	
Technology®),	all	diluted	1:500	in	PBS	and	2%	BSA.	After	1	hour	at	
room temperature, the slices were washed several times in 0.1% 
PBS, transferred to gelatinized slides, mounted with FluorSave™ 
(345789—Merck	 Millipore)	 and	 covered	 with	 coverslips.	 The	
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images were obtained with a Microscopy EVOS® FL Auto Imaging 
System (AMAFD1000—Thermo Fisher Scientific). Quantitative 
analysis of immunofluorescence staining was performed with 
ImageJ software (ImageJ v1.49, National Institute of Health). 
Results are expressed in folds relative to the control group.
2.5 | Analysis of gene expression by real‐time RT‐
PCR (RT‐qPCR)
Total RNA was isolated with Trizol® reagent (Invitrogen) in ac-
cordance with the manufacturer's instructions. The total RNA was 
quantified by spectrophotometry (A260/280 nm) after treatment 
with deoxyribonuclease I (invitrogen) to eliminate genomic DNA 
contamination in accordance with the manufacturer's instructions. 
The cDNA was synthesized with ImProm-II™ Reverse Transcription 
System (Promega) from 1 µg total RNA, following the manufac-
turer's instruction. Quantitative PCR was performed using SYBR® 
Green I (Invitrogen) to detect double-stranded cDNA synthesis. 
Reactions	were	 performed	 in	 25	µL	 volumes	 using	12.5	µL	 of	 di-
luted cDNA, containing a final concentration of 0.2× SYBR® Green 
I (Invitrogen), 100 µmol/L dNTP, 1× PCR Buffer, 3 mmol/L MgCl2, 
0.25	U	Platinum® Taq DNA Polymerase (Invitrogen), and 200 nmol/L 
of each reverse and forward primers classically used as M1 and M2 
phenotypes (Table S1). PCR cycling conditions were as follows: an 
initial	polymerase	activation	step	for	5	minutes	at	95°C,	40	cycles	of	
15	seconds	at	95°C	for	denaturation,	35	seconds	at	60°C	for	anneal-
ing	and	15	seconds	at	72°C	for	elongation.	At	the	end	of	the	cycling	
protocol, a melting curve analysis was included and fluorescence 
was	measured	 from	 60	 to	 99°C,	 all	 cases	 showing	 a	 single	 peak.	
GAPDH was used as reference genes for normalization. Relative ex-
pression	levels	were	determined	with	7500	Fast	Real‐Time	System	
Sequence	Detection	Software	v.2.0.5	(Applied	Biosystems).	Relative	
mRNA expression levels were determined using the target/GAPDH 
method. (Primers are listed in Table S1).
2.6 | Cytokines levels
Concentrations of IL-1β, IL-6, TNF-α, IL-10, and CCL-22 in serum and 
hippocampus were determined using a commercially available sand-
wich ELISA kit (R&D Systems) in a microplate reader according to 
manufacturer's instructions.
2.7 | Nitrite/Nitrate concentration
Nitrite/nitrate concentration was assayed spectrophotometrically 
in serum and hippocampus using Griess reagents (1% sulphanila-
mide	in	5%	phosphoric	acid	and	0.1%	N‐1‐naphthylethylenediamine	
dihydrochloride in bi-distilled H2O [NED solution]) and vanadium 
(III) chloride as previously described.20 A standard curve was run 
simultaneously with each set of samples, and the optical density at 
550	nm	(OD550) was measured using an ELISA microplate reader.
2.8 | Statistics
Data were presented as mean and standard deviation. Molecular data 
were analysed with the ExpressionSuite Software v.1.1, expressed as 
target/GAPDH and percentage change in relation to time 0 (immedi-
ately after CLP surgery), and analysed by two-way analysis of variance 
(ANOVA), followed by Tukey's post hoc test. All tests were analysed 
with SPSS version 20 or GraphPad Prism 4.0. In all comparisons, 
P	<	.05	indicated	statistical	significance.	For	immunohistochemistry,	
immunopositive area was expressed as per cent of total area analysed.
3  | RESULTS
3.1 | Hippocampal expression of M1 markers
Figure 1 shows the kinetics of M1 markers in the hippocampus of 
animals subjected to sepsis, with or without minocycline treatment. 
F I G U R E  1   Hippocampal pattern 
of M1 marker gene expression. M1 
markers	were	measured	24	h,	3,	5,	10	
and 30 d after sepsis induction in the 
hippocampus of animals treated with or 
without minocycline. (A) CD11; (B) iNOS; 
(C) CD16; (D) CD32. * different from that 
at 0 h (dotted line); # different from that 
of CLP + minocycline at the same time; & 
different from that at 3-day (CLP + saline); 
$ different from that at 24 h (CLP + saline). 
Data are expressed as mean ± SD P	<	.05
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There was a significant increase in CD11 expression from 24 hours 
to	30	days,	except	at	5	days,	when	compared	to	expression	levels	at	
time	0	in	septic	animals	(Figure	1A).	At	5	days,	there	was	a	small,	but	
statistically significant, decrease in the expression of CD11 when 
compared to day 3. Generally, minocycline decreased CD11 expres-
sion, reaching statistical significance at 3, 10 and 30 days after CLP 
induction. iNOS expression was consistently increased early after 
CLP, and it kept increasing until day 30 (Figure 1B). The effect of 
minocycline was down-regulation of iNOS expression across all 
studied times. Similar to iNOS, there was a consistent increase in 
CD16 levels early after sepsis induction that was maintained until 
30 days after CLP induction (Figure 1C). Minocycline induced sig-
nificant	 inhibition	of	CD16	expression	during	the	first	5	days	after	
sepsis induction, but had no effects from days 10 to 30. The pattern 
of CD32 expression was somewhat different when compared to that 
of	other	M1	markers	(Figure	1D).	There	was	a	late	(3	and	5	days),	but	
sustained increase in its expression. Minocycline abrogated up-regu-
lation of CD32 expression after sepsis.
3.2 | Hippocampal expression of M2 markers
Figure 2 shows the kinetics of M2 markers in the hippocampus of 
animals subjected to sepsis, with or without minocycline treatment. 
CD206 expression significantly decreased early after sepsis induc-
tion, followed by significant increase after 3 days, which was main-
tained until day 30 (Figure 2A). Interestingly, minocycline transitorily 
increased CD206 expression after 24 hours, but did not interfere in 
CD206 expression at any other time (Figure 2A). TGF had an expres-
sion pattern similar to CD206; there was an early decrease followed 
by	a	late	increase	in	its	expression	from	days	5	to	30	after	CLP,	and	
minocycline transiently increased its expression after 24 hours, and 
5	and	10	days	when	compared	to	CLP	(Figure	2B).	However,	30	days	
after sepsis induction, CLP animals had higher levels of TGF when 
compared to minocycline-treated animals (Figure 2B). Figure 2C 
shows CCL-22 expression after CLP. There was a transient, but signifi-
cant decrease 3 days after CLP. Minocycline treatment prevented the 
decrease of CCL-22 expression at day 3, but in general, there was no 
regulation of this marker after sepsis. In addition, IL-10 significantly in-
creased 3 days after CLP, with these levels being maintained until day 
30. Again, minocycline induced an early increase in IL-10 expression 
at 24 hours, and from day 3 to 30, decreased its expression after CLP.
3.3 | Hippocampal levels of M1 cytokines and 
nitrite/nitrate
Figure 3 shows the kinetics of M1 cytokines in the hippocampus of 
animals subjected to sepsis, treated or not with minocycline. TNF-α 
(A), IL-6 (B) and IL-1 (C) levels remained increased until 10 days after 
sepsis, decreasing to basal levels by day 30. Minocycline was able to 
decrease these levels at all analysed times. Nitrite/nitrate levels (D) 
were significantly increased until day 10 when compared to time 0. 
Minocycline	reduced	these	levels	at	all	times	except	on	day	5.
3.4 | Hippocampal levels of M2 cytokines
There was no alteration in CCL-22 levels until day 30 (Figure 4A). 
IL-10 levels peaked at days 3 and 10 and remained elevated for up to 
30	days	(Figure	4B).	Minocycline	increased	IL‐10	levels	5	days	after	
sepsis (Figure 4B).
3.5 | Hippocampal immunofluorescence of CD11b 
(M1 marker)
Figure	5	shows	the	kinetics	of	CD11b	(M1	marker)	by	immunofluo-
rescence.	There	was	a	progressive	increase	in	CD11	+	cells	for	5	days	
until	30	days	after	CLP.	From	day	5	to	day	30,	minocycline	decreased	
the number of CD11+ cells.
3.6 | Hippocampal immunofluorescence of arginase 
(M2 marker)
Minocycline treatment resulted in the early appearance of argin-
ase+	cells	(from	5	days	after	CLP),	and	the	number	of	positive	cells	in	
this group was higher when compared to that after CLP at 30 days 
(Figure 6).
3.7 | Serum levels of M1/M2 cytokines and nitrite/
nitrate
To determine the effect of i.c.v. administration of minocycline on 
systemic inflammatory response, levels of M1/M2 cytokines and 
nitrite/nitrate were determined in the serum of animals subjected 
to CLP treated with or without minocycline. As expected, TNF-α, 
IL-6 and IL-1β increased early after CLP induction and peaked from 
24	 hours	 to	 5	 days	 after	 (Figure	 7	 A‐C).	 These	M1	 cytokines	 re-
mained slightly, but significantly, increased until 10 to 30 days after 
sepsis. Minocycline attenuated the magnitude of the M1 cytokine 
peak and the duration of this increase (Figure 7A-C). The same be-
haviour was observed for serum nitrite/nitrate levels (Figure 7D). 
Conversely, CCL-22 and IL-10 increased late after sepsis (from day 3 
to day 30), but i.c.v. minocycline did not modulate IL-10 and CCL-22 
serum levels (Figure 7E-F).
4  | DISCUSSION
Here, we demonstrated, using gene expression, cytokine levels and 
surface markers, that early after sepsis, there is a preponderant up-
regulation of M1 microglial markers, and as we hypothesized, this 
pattern did not later switch to the M2 phenotype. We have demon-
strated that up-regulation of both M1 and M2 markers co-exists up 
to 30 days after sepsis induction. In addition, minocycline induced a 
down-regulation, predominantly, of M1 markers, suggesting that its 
protective effects after sepsis are due to, at least in part, the induc-
tion of a predominant M2 phenotype.
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The multiple activation of phenotypes in microglial cells is a 
relatively new perception and is mainly derived from macrophage 
literature. In this context, specifically in the sepsis field, there are 
few reports about the behaviour of different microglial phenotypes. 
For instance, D'Avila et al21 demonstrated that aged mice produced 
higher levels of pro-inflammatory cytokines (IL-1β and IL-6) as well 
as pro-resolution (IL-10 and IL-4) in the brain after episodic systemic 
inflammation when compared to young animals. Additionally, aged 
mice presented dystrophic microglia at basal level and did not change 
morphology in the response to systemic inflammation.21 We recently 
demonstrated that the depletion of microglia before sepsis develop-
ment is associated with acute exacerbation of brain inflammation. 
Furthermore, microglia repopulation is able to revert this, mainly 
inducing a shift to M2 phenotype in these animals.22 Additionally, 
in septic humans, it was found pro-inflammatory microglia, and the 
most important difference between patients with sepsis and con-
trols was the induction of iNOS in microglia. Interestingly, the ex-
pression of the P2RY12 (homeostatic microglia marker) was similar 
in control and septic brains.23
Based on macrophage literature, it is classically expected that 
within 24 hours after insult, monocytes are recruited from circula-
tion, and they traffic into an infection site, where they mature into 
classically activated macrophages, also called M1 macrophages.24,25 
Later, macrophages usually switch to M2 phenotypes that are in-
volved in inflammation resolution.24,25 Whether proliferating microg-
lia might migrate and settle in specific brain areas, and the phenotype 
associated with acute and late phases of sepsis where they are possi-
bly involved in re-establishing tissue homeostasis, is not known.
F I G U R E  2   Hippocampal pattern 
of M2 markers gene expression. M2 
markers	were	measured	24	h,	3,	5,	10	
and 30 d after sepsis induction in the 
hippocampus of animals treated with or 
without minocycline. CD206 (A); TGF (B); 
CCL-22 (C); IL-10 (D). * different from that 
at 0 h (dotted line); # different from that 
of CLP + minocycline at the same time; & 
different from that at 3 d (CLP + saline); $ 
different from that at 24 h (CLP + saline). 
Data are expressed as mean ± SD P	<	.05
F I G U R E  3   Hippocampal pattern of 
M1 cytokines/ nitrite levels. M1 cytokines 
levels	were	measured	24	h,	3,	5,	10	
and 30 d after sepsis induction in the 
hippocampus of animals treated with or 
without minocycline. (A) TNF; (B) IL-6; (C) 
IL-1; (D) nitrite/nitrate. * different from 
that at 0 h (dotted line); # different from 
CLP + minocycline at the same time. Data 
are expressed as mean ± SD P	<	.05
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We observed that all M1 markers were initially up-regulated in 
comparison to CLP time 0, and this was even more apparent when 
compared to the kinetics of M2 markers. Interestingly, minocycline 
seemed to act more robustly on M1 markers. The activation of M1 
without counterbalancing M2 could be important to the brain's 
acute response to systemic inflammation, but may present nega-
tive results in the long-term, since minocycline improved long-term 
cognitive deficits in sepsis survivor.3 Minocycline seems to induce a 
more balanced response, mainly at early times, decreasing brain M1 
markers and attenuating a systemic inflammatory response. Studies 
have shown that minocycline reduces the levels of pro-inflammatory 
cytokines,2 and here we demonstrated that it acts on different as-
pects of microglia activation (gene expression, membrane markers 
and cytokine secretion). Minocycline was also able to significantly 
decrease iNOS expression and nitrite/nitrate levels, which suggests 
an indirect protective function of minocycline by decreasing free 
radical production,24,26 which was previously thought to be associ-
ated with long-term cognitive impairment after sepsis.27
M2 macrophages, which demonstration anti-inflammatory prop-
erties, are classically defined by the expression of the scavenger 
(CD163) and mannose (CD204/206) receptors as well as enhanced 
expression and secretion of immunosuppressive cytokines, such as 
IL-10 and transforming growth factor (TGF)-β1.28 In addition, the ex-
pression of arginase 1 (Arg1) counteracts the effects of iNOS from 
M1 macrophages.25 The kinetics of M2 during sepsis development 
seems to be a regulatory response to counterbalance M1 activation. 
However, M2 markers appear late after sepsis induction and the mag-
nitude of their up-regulation is generally less robust when compared 
to M1 markers. This is further reinforced by the fact that the M1 cy-
tokines, IL1, IL-6 and TNF are consistently increased in the hippocam-
pus late after sepsis, and IL-10 has some peaks during sepsis evolution 
and CCL-22 is not increased at all. In this context, minocycline seems 
to decrease M1 markers and simultaneously increase M2, resulting in 
a more balanced phenotype expression. Zhao et al29 showed that mi-
nocycline suppressed the production of pro-inflammatory molecules, 
reduced Iba1 (+) cells and reversed the reduction of M2 microglial 
markers in animal models of maternal sleep deprivation.
One interesting finding is the fact that the modulation of brain 
inflammation seems to regulate systemic inflammatory response. 
The i.c.v. administration of minocycline decreased the magnitude 
of serum M1 response, and this mirrored, to some extent, the in 
situ effect of minocycline. This suggests a crosstalk between mi-
croglia and macrophage phenotypes that could be driven by brain 
cytokine patterns. It is possible that the magnitude of brain inflam-
mation modulates some aspects of brain-systemic inflammatory 
response, such as the integrity of the blood-brain barrier, acti-
vation of endothelial cells, and activation of the anti-cholinergic 
or hypothalamic-pituitary-adrenal axes.30,31 For example, it was 
demonstrated that minocycline selectively protects cholinergic 
neurons	from	p75‐saporin	toxicity	32 and there is a crosstalk be-
tween hippocampal and splenic inflammation in knockout mice for 
the vesicular acetylcholine transporter.33
One relevant point that was not addressed by our study is 
whether minocycline administration improves mortality in this 
model. Despite it was not the main objective of this study, this is 
a clinically and scientifically relevant question. It is known that 
systemic administration of minocycline improves mortality in CLP 
model,34 but this could be secondary to its antibiotic effect. When 
administered directly in the brain, minocycline improved brain in-
flammation and dysfunction,3,35 and this could impact in survival. 
Further studies are necessary to specifically answer this.
Some limitations must be highlighted. First, gene expression 
analysis was not performed in isolated microglia from septic rats; 
thus, because neurons, glia and endothelial cells also express some 
of the analysed markers, we cannot ascertain whether our results re-
flect only the microglia expression of these markers. This limitation 
is minimized by the fact that microglia phenotypes were determined 
by three different methods. Second, blood-borne leucocytes can 
F I G U R E  4   Hippocampal pattern of M2 cytokines levels. M2 
cytokines	levels	were	measured	24	h,	3,	5,	10	and	30	d	after	sepsis	
induction in the hippocampus of animals treated with or without 
minocycline. (A) CCL-22; (B) IL-10. * different from that at 0 h 
(dotted line); # different from CLP + minocycline at the same time. 
Data are expressed as mean ± SD P	<	.05
F I G U R E  5   DAPI (nuclei- blue); CD11b (M1 marker– red); IBA-1+ (microglial marker—green) was determined by immunofluorescence, 24 h, 
5	and	30	d	after	sepsis	in	the	hippocampus	of	animals	treated	with	or	without	minocycline.	A,	24	h;	B,	5	d;	C,	30	d;	D,	corresponding	graphs.	
Image details are presented. Double positive cells (CD11b + IBA-1+) were counted in both groups. T-test for independent samples. P = .18; 
P = .03
     |  7MICHELS Et aL.
8  |     MICHELS Et aL.
     |  9MICHELS Et aL.
also reach the brain during sepsis development, and they probably 
share the same phenotypes and are inhibited by minocycline 36; thus, 
some of the observed effects could be associated with blood-borne 
leucocytes. Third, despite being highly improbable that low doses 
of i.c.v. administered could directly inhibit blood-borne leucocytes, 
we cannot ascertain whether the effects of minocycline on systemic 
inflammation are only secondary to decreased brain inflammation.
5  | CONCLUSION
In conclusion, early activation of M1 microglia is followed by an overlap 
of both M1 and M2 phenotypes. The beneficial effects of minocycline 
on sepsis-associated brain dysfunction may be related to its effects 
predominantly on the M1 phenotype. These findings might reflect 
the importance of the M1/M2 balance in brain repair after systemic 
inflammation.
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F I G U R E  7   Serum pattern of M1/M2 
cytokines and nitrite levels. Cytokines and 
nitrite/nitrate levels were measured 24 h, 
3,	5,	10	and	30	d	after	sepsis	induction	in	
the hippocampus of animals treated with 
or without minocycline. A, TNF; B, IL-6; 
C, IL-1; D, nitrite/nitrate; E, CCL-22; F, 
IL-10. *Different from that at 0 h (dotted 
line); # different from CLP + minocycline 
at the same time. Data are expressed as 
mean ± SD P	<	.05
F I G U R E  6   DAPI (nuclei—blue); arginase (M2 marker—red); IBA-1+ (microglial marker—green) was determined by immunofluorescence, 
24	h,	5	and	30	d	after	sepsis	in	the	hippocampus	of	animals	treated	with	or	without	minocycline.	A,	24	h;	B,	5	d;	C,	30	days;	D,	corresponding	
graphs. Image details are presented. Double positive cells (CD11b + IBA-1+) were counted in both groups. t Test for independent samples. 
P = .74; P = .03
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